Oncología Médica Traslacional y Terapia Individualizada del Cáncer

Kawazoe, A; Xu, RH; Garcia-Alfonso, P; Passhak, M; Teng, HW; Shergill, A; Gumus, M; Qvortrup, C; Stintzing, S; Towns, K; Kim, TW; Shiu, KK; Cundom, J; Ananda, S; Lebedinets, A; Fu, R; Jain, R; Adelberg, D; Heinemann, V; Yoshino, T; Elez, E.

Lenvatinib Plus Pembrolizumab Versus Standard of Care for Previously Treated Metastatic Colorectal Cancer: Final Analysis of the Randomized, Open-Label, Phase III LEAP-017 Study

JOURNAL OF CLINICAL ONCOLOGY. 2024; 42(24): Nº de citas: 28 [doi:10.1200/JCO.23.02736]

Cedillo, S; González-Domínguez, A; Ivanova-Markova, Y; López, RL; Cobo, SLT; Pedrosa, JAP.

Cost-Utility Analysis of Adjuvant Olaparib for Germline BRCA1/2-Mutated, High-Risk HER2-Negative Early Breast Cancer in Spain

Pharmacoeconomics-Open. 2024; 8(6): 887-896 [doi:10.1007/s41669-024-00518-2]

Moran, LO; Mateo, FJP; Balanyà, RP; Revuelta, JR; Martinez, SR; Fombella, JPB; Vázquez, EMB; Caro, NL; Langa, JM; Fernández, MS.

SEOM clinical guidelines on venous thromboembolism (VTE) and cancer (2023)

CLINICAL & TRANSLATIONAL ONCOLOGY. 2024; 26(11): 2877-2901 Nº de citas: 2 [doi:10.1007/s12094-024-03605-2]

López-Jiménez, C; Gutiérrez, A; Caamaño, DSJ; Alsar, JS; Villa, JLC; Abad, CB; Morón, B; Morán, LO; Martín, M; Martín, AJM.

Impact of COVID-19 in the incidence of venous thromboembolism (VTE) and clinical outcomes in cancer patients: a cohort study

CLINICAL & TRANSLATIONAL ONCOLOGY. 2024; 27(2): 756-769 Nº de citas: 1 [doi:10.1007/s12094-024-03635-w]

Lope, V; Guerrero-Zotano, A; de Larrea-Baz, NF; Antolín, S; Viñuales, MB; Bermejo, B; Ruiz-Moreno, E; Baena-Cañada, JM; París, L; Antón, A; Chacón, JI; Muñoz, M; García-Sáenz, JA; Olier, C; Rovira, PS; Lanza, AA; González, S; Brunet, J; Oltra, A; Bezares, S; Rosell, L; Pérez-Gómez, B; Pastor-Barriuso, R; Martín, M; Pollán, M.

Cross-sectional and longitudinal associations of adherence to WCRF/AICR cancer prevention recommendations with health-related quality of life in breast cancer survivors. Health-EpiGEICAM study

JOURNAL OF NUTRITION HEALTH & AGING. 2024; 28(8): Nº de citas: 1 [doi:10.1016/j.jnha.2024.100312]

Conte, P; Ciruelos, E; Curigliano, G; De Laurentiis, M; Del Mastro, L; Gennari, A; Llombart, A; Martìn, M; Poggio, F; Prat, A; Puglisi, F; Saura, C.

" Positioning of tucatinib in the new clinical scenario of HER2-positive metastatic breast cancer: An Italian and Spanish consensus paper" "

BREAST. 2024; 76: Nº de citas: 4 [doi:10.1016/j.breast.2024.103742]

Curigliano, G; Jimenez, MM; Shimizu, T; Keam, B; Meric-Bernstam, F; Rutten, A; Glaspy, J; Schuler, PJ; Parikh, NS; Ising, M; Hassounah, N; Wu, J; Leyk, M; Chen, X; Burks, H; Chaudhury, A; Otero, J; Cabanas, EG.

A phase I trial of LHC165 single agent and in combination with spartalizumab in patients with advanced solid malignancies

Esmo Open. 2024; 9(8): Nº de citas: 3 [doi:10.1016/j.esmoop.2024.103643]

Chatziioannou, E; Higuita, LMS; Kreft, S; Kandolf, L; Dujovic, B; Reinhardt, L; Tamara, E; Marquez-Rodas, I; Fortuna, ARFP; Nübling, A; Niessner, H; Forschner, A; Garbe, C; Popovic, A; Mirjana, B; Meier, F; Eigentler, T; Leiter, U; Flatz, L; Sinnberg, T; Amaral, T.

Nomogram for predicting survival after first-line anti-PD-1-based immunotherapy in unresectable stage IV melanoma: a multicenter international study

Esmo Open. 2024; 9(8): Nº de citas: 2 [doi:10.1016/j.esmoop.2024.103661]

Somoza-Fernández, B; Escudero-Vilaplana, V; Collado-Borrell, R; Perez-Ramírez, S; Villanueva-Bueno, C; Montero-Antón, MD; Herranz-Alonso, A; Sanjurjo-Saez, M.

Severe neutropenia probably caused by enzalutamide and abiraterone in a prostate cancer patient

JOURNAL OF ONCOLOGY PHARMACY PRACTICE. 2024; 30(7): 1268-1273 [doi:10.1177/10781552241264530]

Johnston, SRD; Rugo, HS; Tolaney, SM; Fernandez, MM; Wei, R; Martin, M.

Abemaciclib plus endocrine therapy for HR+, HER2-, node-positive, high-risk early breast cancer: a plain language summary of the monarchE study

Future Oncology. 2024; 20(28): 2037-2048 [doi:10.1080/14796694.2024.2362095]

Gutiérrez, F; López, L; Carlos, G; Tiraboschi, JM; Portu, J; García-Fraile, L; del Toro, MG; Bernal, E; Rivero, A; García-Abellán, J; Flores, J; González-Cordón, A; Martínez, O; Bravo, J; Rosado, D; Montero, M; Sirera, G; Torralba, M; Galindo, MJ; Macías, J; Gónzalez-Cuello, I; Boix, V; Vivancos, MJ; Dios, P; Blanco, JR; Padilla, S; Fernández-González, M; de la Tabla, AGO; Martínez, E; Masiá, M.

Early Detection of Cancer and Precancerous Lesions in Persons With Human Immunodeficiency Virus (HIV) Through a Comprehensive Cancer Screening Protocol

CLINICAL INFECTIOUS DISEASES. 2024; 80(2): 371-380 Nº de citas: 1 [doi:10.1093/cid/ciae359]

Arija, JAA; del Muro, XG; Caro, RL; Mendez-Vidal, MJ; Perez-Valderrama, B; Aparicio, J; Duran, MAC; Diaz, CC; Duran, I; Gonzalez-Billalabeitia, E.

SEOM-GG clinical guidelines for the management of germ-cell testicular cancer (2023)

CLINICAL & TRANSLATIONAL ONCOLOGY. 2024; 26(11): 2783-2799 Nº de citas: 4 [doi:10.1007/s12094-024-03532-2]

Dent, R; André, F; Gonçalves, A; Martin, M; Schmid, P; Schütz, F; Kümmel, S; Swain, SM; Bilici, A; Loirat, D; Valencia, RV; Im, SA; Park, YH; De Laurentis, M; Colleoni, M; Guarneri, V; Bianchini, G; Li, H; Machackova, ZK; Mouta, J; Deurloo, R; Gan, X; Fan, M; Mani, A; Swat, A; Cortés, J.

IMpassion132 double-blind randomised phase III trial of chemotherapy with or without atezolizumab for early relapsing unresectable locally advanced or metastatic triple-negative breast cancer

ANNALS OF ONCOLOGY. 2024; 35(7): 630-642 Nº de citas: 21 [doi:10.1016/j.annonc.2024.04.001]

Márquez-Rodas, I; Alvarez, A; Arance, A; Valduvieco, I; Berciano-Guerrero, MA; Delgado, R; Soria, A; Campos, FL; Sánchez, P; Romero, JL; Martin-Liberal, J; Lucas, A; Díaz-Beveridge, R; Conde-Moreno, AJ; de la Gala, MDA; García-Castaño, A; Prada, PJ; Cao, MG; Puertas, E; Vidal, J; Foro, P; de la Rosa, CA; Corona, JA; Cerezuela-Fuentes, P; López, P; Luna, P; Aymar, N; Puértolas, T; Sanagustín, P; Berrocal, A.

Encorafenib and binimetinib followed by radiotherapy for patients with BRAF^V600-mutant melanoma and brain metastases (E-BRAIN/GEM1802 phase II study)

NEURO-ONCOLOGY. 2024; 26(11): 2074-2083 Nº de citas: 4 [doi:10.1093/neuonc/noae116]

Cerezuela-Fuentes, P; Gonzalez-Cao, M; Puertolas, T; Manzano, JL; Maldonado, C; Yelamos, O; Berciano-Guerrero, MA; Martin-Liberal, J; Muñoz-Couselo, E; Espinosa, E; Drozdowskyj, A; Berrocal, A; Soria, A; Marquez-Rodas, I; Martin-Algarra, S; Quindos, M; Puig, S.

Access to systemic treatment of non-melanoma skin cancer in Spain: a survey analysis

CLINICAL & TRANSLATIONAL ONCOLOGY. 2024; 27(1): 386-391 [doi:10.1007/s12094-024-03583-5]

Takashima, A; García-Alfonso, P; Manneh, R; Besen, AA; Hong, YS; Cuyle, PJ; Yanez, P; Burge, M; Yoshino, T; Kim, TW; Cui, K; Li, CX; Jain, R; Adelberg, D; Taieb, J.

Olaparib with or without bevacizumab versus bevacizumab plus a fluoropyrimidine as maintenance therapy in advanced colorectal cancer: The randomized phase 3 LYNK-003 study

EUROPEAN JOURNAL OF CANCER. 2024; 205: Nº de citas: 5 [doi:10.1016/j.ejca.2024.114036]

López, BH; Cardeña-Gutiérrez, A; Ortiz, AG; López, AG; López, AMG; Alves, AN; Daffós, PR; Sánchez, CAR; Pérez, ARR; Santos, VS; Grau, SS; García, RS; Palmer, MAS.

Exercise in cancer patients: assistance levels and referral pathways-a position statement from the Spanish Society of Medical Oncology

CLINICAL & TRANSLATIONAL ONCOLOGY. 2024; 27(1): 108-116 Nº de citas: 5 [doi:10.1007/s12094-024-03546-w]

Cánovas, MS; Hernández, MAM; Adoamnei, E; Lavin, DC; Garay, DF; Verdúguez, TQ; Revuelta, JR; Verdejo, FJG; Adrián, SG; Pérez, AIF; García, MEG; Robles, JL; Mendiola, J; Martín, AJM.

Immune checkpoint inhibitors-associated thrombosis in patients with head and neck cancer: a study of the Spanish society of medical oncology (SEOM) thrombosis and cancer group

CLINICAL & TRANSLATIONAL ONCOLOGY. 2024; 27(1): 175-181 Nº de citas: 1 [doi:10.1007/s12094-024-03570-w]